A Patent Is Not a Program

A Patent Is Not a Program

A company announced this morning that it has filed two U.S. patent applications for treating muscle loss in microgravity. Long-duration spaceflight, the release explains, means long stretches in an environment where muscle quietly wastes away; no drug is approved for the condition; and an oral medicine would fit the physics of a capsule better than an injection would, because mass, volume and crew time are scarce up there. Read to the end and you reach the paragraph where the lawyers write the truth: the products are preclinical. Neither has been tested in humans in space. No trial exists for this population. And the company is not a party to any agreement with NASA, any space agency, or any commercial space operator. The press release has out-argued its own headline before you finish the first page.

The company is NorthStrive Biosciences, a wholly owned subsidiary of PMGC Holdings (Nasdaq: ELAB). The two filings — U.S. Application Nos. 19/774,556 and 19/774,575 — cover its lead assets, EL-22 and EL-32.

The lazy objection would be that microgravity muscle loss isn't a real disease. It is, and stopping there costs us the better argument. Muscle loss from mechanical unloading — gravity gone, so nothing loads your muscles and they shrink — is one of the most studied problems in human spaceflight. Without countermeasures, bones shed roughly 1% of their density a month and muscles follow; crews already spend about two hours a day exercising to hold the line; and NASA itself says today's equipment is too bulky for the long missions it is planning beyond low Earth orbit. The target is real. The science is real, too: myostatin is a protein that acts as a brake on muscle growth, and block it in the standard simulated-weightlessness mouse models and the muscle loss stops, as a well-cited 2020 study showed. NASA has even flown a myostatin-inhibitor experiment to the station. So if you want to attack this company, don't attack the disease. It exists. Attack the customer. It doesn't.

That is a shame, because the underlying idea is one of the more interesting in muscle biology right now. EL-22 is an engineered Lactobacillus — a live bacterium you swallow — designed to display fragments of your own myostatin to your immune system, training it to quietly neutralize the molecule. A self-vaccine against your own brake. EL-32 does the same trick against two targets at once, adding activin A, a sibling brake. Swallowed, not injected, taken by mouth: if an oral version works as claimed, it is exactly how an operator counting grams and minutes on a Mars trajectory would want a muscle drug to arrive. For a few paragraphs the space story does real work. And the genuinely odd part is that the platform's real customer is already on Earth: the lead candidate's actual pitch is preserving muscle in people losing it on GLP-1 weight-loss drugs, a market born from a population where more than 40% of U.S. adults already live with obesity.

Then you notice what the same release concedes. The totality of human experience with this platform appears to be one 37-person Phase 1 safety study, run in Seoul by the Korean company the asset came from, measuring tolerability only — never efficacy, never anyone's muscle, never with gravity removed. A Phase 1 study is the first, small test of safety in people; it is a very long way from a drug. No microgravity human data, no trial, no agreement with anyone who launches anything. I admire the honesty; it is a better argument against the story than any critic could write. Preliminary FDA feedback, the company says, points toward a U.S. Phase 2 trial — the larger trial that actually tests whether a drug works — of EL-22 combined with those weight-loss drugs. That is the business. It currently sits at: we're evaluating pathways, subject to available financing.

Meanwhile, look at the throughput. In February the company filed ten patent applications for muscle growth in farmed animals. In April, formulations for sarcopenia and disuse atrophy. More for obesity. Now space. Once you see the cadence, a pattern that matters to a shareholder asserts itself: each release's verb is filed, never found. A patent application costs little to file and years to be examined; the press release announcing it is free today. When a company's news flow is dominated by claims rather than data, the filings are not the product. The announcements are.

The deepest tell sits in a quiet July release: the company is running a comparability study to prove that the Lactobacillus it makes in its own facility expresses myostatin the same way the material from its Korean licensor does. A company still trying to establish that its product reproducibly exists, claiming territory in orbit while it does.

The parent keeps the house running the way microcaps do: it buys small cash-flowing manufacturers — aerospace machining shops, chip-packaging companies — to fund the molecules, and it announced a 1-for-10 reverse stock split, the share consolidation companies use to avoid a delisting for a sub-dollar price, two days before this filing. The most recent quarter brings the scale into focus: about $2 million of revenue, and a net loss from continuing operations — losses from the businesses it intends to keep — near $8 million, roughly four times the year-earlier loss, on total assets of about $13 million. That is a company multiplying options because it has not yet got itself to do the thing.

The strongest case for the space filings is that space health is a real, budding category: commercial stations, private crews, the lunar program, a Mars window opening within a decade, and muscle loss squarely on the known-risk list. The drug that solves microgravity is also the muscle drug for aging and obesity on Earth, so the patents are nearly free optionality. I want to believe it; the science is genuinely good. But optionality you cannot afford to exercise is not a hedge. In this business a patent is a claim about the future and a contract is a claim about the present; only a claim in the present turns optionality into position. A company serious about space health would start producing present-tense evidence at any size — a grant, a partnership, a letter of intent, a mention in a government solicitation. This one's own release says none of that exists. Positioning means being found in a position by somebody else. Filing means being alone in a field you drew for yourself.

So here is the test, and you can run it on any early-stage company, not just this one. Count the press releases and watch the verb. Progress is when filed for becomes found, when claims become data, when we intend becomes someone agreed. A company serious about a molecule runs out of things to announce about it; it does not restock itself from a shelf of diseases the molecule might someday touch. The order of operations in making something people want never changes: first the product exists reproducibly, then its effect is real in people, then someone pays. Patents precede all of that and imply none of it. A space patent is not a space program. File all the claims you want — the market counts customers, not claims.